Why is the Avita Medical share price rocketing 24% today?

This healthcare share is ending the week on a very positive note. But why?

| More on:
Vanadium Resources share price person riding rocket indicating share price increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Avita Medical Inc (ASX: AVH) share price is catching the eye on Friday.

In morning trade, the regenerative medicine company's shares are up 24% to $3.96.

Why is the Avita Medical share price rocketing?

Investors have been picking up Avita Medical's shares this morning after it released its third quarter update and revealed strong top line growth.

Here's a summary of how it performed for the three months ended 30 September:

  • Commercial revenue up 51% to US$13.5 million
  • Gross margin of 84.5% for the quarter
  • Operating expenses up 48% to US$21 million
  • Net loss widened 55% to US$8.7 million
  • Cash on hand of US$60.1 million

Despite its sizeable loss, management believes the regenerative medicine company is well-positioned and has sufficient cash to meet its profitability goals. This could explain the strong rise in the Avita Medical share price today.

This should be supported by the Recell Go product, which management appears confident will be granted US FDA approval next year.

The company's chief executive officer, Jim Corbett, commented:

We continue to execute our growth strategy, paving the way to profitability. We are diligently working through supplemental in-house testing to support the FDA's review of our PMA supplement for RECELL GO. Once complete, we expect to submit a response to the FDA's open questions on February 28, 2024. Under the Breakthrough Device program, we anticipate FDA approval on May 30, 2024, which positions us for a launch the following day.

This sentiment was echoed by its chief financial officer, David O'Toole, he adds:

We have achieved significant commercial revenue growth rates for the last three quarters of 40%, 42% and 51%, respectively, over the same periods in the previous year. Further, we remain confident that our cash reserves position us to achieve our goals and reach profitability in 2025.

Looking ahead, the company expects its strong top-line growth to continue. It is guiding to fourth-quarter commercial revenue growth of 64% to 73% over the prior corresponding period.

Following today's gain, the Avita Medical share price is now up 100% in 2023.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Avita Medical. The Motley Fool Australia has recommended Avita Medical. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »

A male doctor wearing a white doctor's coat shrugs and holds his hands up to indicate the unimpressive CSL share price as a result of OOVID-19
Healthcare Shares

Here's the earnings forecast out to 2030 for CSL shares

How healthy will the profit growth be in the coming years?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »